TRVN - Trevena Inc logo

TRVN

Trevena Inc

Rev โ€”top 1%10Y
Hold

Trevena, Inc. develops and commercializes novel biopharmaceuticals targeting central nervous system disorders. Key products include OLINVYK for acute pain management and investigational drugs for chronic pain and opioid use disorder.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Score
Net Growth15.52%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-82.53%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.1
Net Growth-36.85%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth17x
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth31.52%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend40%
Revenue Consistency
All Time
Scoreโ€”
Net Growth31.52%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Trevena Inc fundamental performance

Between 2018 and 2023, revenue declined from $ 5M to $ 3M and net income went from -$ 30M to -$ 40M. Revenue increased in 2 of those 5 years; net income in 2.

Trevena Inc currently holds a 5-year HDB Score of 4.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-11
$ 0.00โ€”
1 Year2025-08-12
$ 0.26-99.62%
5 Years2021-08-12
$ 781.25-100.00%
10 Years2016-08-12
$ 4.36K-100.00%
All Time2014-01-31
$ 4.06K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2024$ 546K-$ 34M$ 13M
2023$ 3M-$ 40M$ 32M
2022-$ 418K-$ 53M$ 38M
2021$ 567K-$ 51M$ 66M
2020$ 3M-$ 29M$ 109M
2019$ 31K-$ 24M$ 35M
2018$ 5M-$ 30M$ 61M
2017$ 0.00-$ 71M$ 66M
2016$ 3M-$ 102M$ 110M
2015$ 6M-$ 50M$ 172M
IPO2014$ 0.00-$ 49M$ 106M

Explore beyond TRVN

You're looking at Trevena Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies